Evaluation of the efficacy of NBUVB (narrow band UVB) phototherapy plus pioglitazone versus NBUVB phototherapy alone in the treatment of plaque type psoriasis

Clinical trial of comparison of the efficacy of NBUVB phototherapy plus pioglitazone versus NBUVB phototherapy alone in the reduction of PASI score in patients with plaque type psoriasis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016091918607N2

Enrollment

Registered

2017-02-28

Start date

2016-11-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis. Plaque psoriasis

Interventions

Treatment - Drugs

Intervention 1: Pioglitazone group: NBUVB phototherapy three times a week plus pioglitazone (tablet 30 mg, 1 tab/ day, oral). Intervention 2: Placebo group: NBUVB three times a week plus placebo (the

Pioglitazone group: NBUVB phototherapy three times a week plus pioglitazone (tablet 30 mg, 1 tab/ day, oral)

Placebo group: NBUVB three times a week plus placebo (the same as pioglitazone)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with plaque type psoriasis; indication of NBUVB phototherapy Exclusion criteria: age under 18 years; treatment with phototherapy or systemic drugs of psoriasis during the last 3 months; pregnancy; lactation; congestive heart failure; renal diseases; liver diseases; pulmonary diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
PASI 75. Timepoint: Before treatment and 10 weeks after starting treatment. Method of measurement: Examination.	—

Secondary

Measure	Time frame
Dermatology Life Quality Index (DLQI). Timepoint: Before treatment and 10 weeks after starting treatment. Method of measurement: Questionnaire.;Adverse effects. Timepoint: every month after starting treatment. Method of measurement: examination and asking from the patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Ghiasi

Department of Dermatology, Tehran University of Medical Sciences

mghiasi@tums.ac.ir+98 21 5561 8989

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026